CA3138811A1 - Antibiotic cannabinoid-terpene formulations - Google Patents

Antibiotic cannabinoid-terpene formulations Download PDF

Info

Publication number
CA3138811A1
CA3138811A1 CA3138811A CA3138811A CA3138811A1 CA 3138811 A1 CA3138811 A1 CA 3138811A1 CA 3138811 A CA3138811 A CA 3138811A CA 3138811 A CA3138811 A CA 3138811A CA 3138811 A1 CA3138811 A1 CA 3138811A1
Authority
CA
Canada
Prior art keywords
infection
cannabinoid
formulation
sesquiterpene
daptomycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3138811A
Other languages
English (en)
French (fr)
Inventor
Charles J. Thompson
Mark C. PRYJMA
Dana M. LAMBERT
Manisha Dosanjh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of CA3138811A1 publication Critical patent/CA3138811A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3138811A 2019-05-06 2020-05-06 Antibiotic cannabinoid-terpene formulations Pending CA3138811A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962843687P 2019-05-06 2019-05-06
US62/843,687 2019-05-06
PCT/CA2020/050613 WO2020223811A1 (en) 2019-05-06 2020-05-06 Antibiotic cannabinoid-terpene formulations

Publications (1)

Publication Number Publication Date
CA3138811A1 true CA3138811A1 (en) 2020-11-12

Family

ID=73050953

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3138811A Pending CA3138811A1 (en) 2019-05-06 2020-05-06 Antibiotic cannabinoid-terpene formulations

Country Status (11)

Country Link
US (3) US20220218654A1 (enExample)
EP (1) EP3965794A4 (enExample)
JP (1) JP2022532116A (enExample)
KR (1) KR20220005066A (enExample)
CN (1) CN113710263A (enExample)
AU (1) AU2020270175A1 (enExample)
CA (1) CA3138811A1 (enExample)
IL (1) IL287729A (enExample)
MX (1) MX2021013656A (enExample)
SG (1) SG11202110779SA (enExample)
WO (1) WO2020223811A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021013656A (es) * 2019-05-06 2022-01-06 Univ British Columbia Formulaciones antibioticas de cannabinoides-terpenos.
KR102524364B1 (ko) * 2022-10-24 2023-04-24 전북대학교산학협력단 칸나비디올 및 타우린을 포함하는 치주염 예방 또는 치료용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630507B1 (en) 1998-04-21 2003-10-07 The United States Of America As Represented By The Department Of Health And Human Services Cannabinoids as antioxidants and neuroprotectants
US7323576B2 (en) 2004-10-01 2008-01-29 Alphora Research Inc. Synthetic route to dronabinol
WO2012012498A2 (en) 2010-07-20 2012-01-26 Pulmatrix, Inc. Use of trp channel agonists to treat infections
CN107405314A (zh) * 2015-02-27 2017-11-28 埃布公司 包含纯化的大麻素与至少一种类黄酮、萜或矿物质的组合的组合物
AU2016225026A1 (en) * 2015-02-27 2017-09-07 Canopy Growth Corporation Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
EP3380096A4 (en) * 2015-11-24 2019-10-23 Constance Therapeutics, Inc. CANNABIS OIL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
WO2018011813A1 (en) 2016-07-14 2018-01-18 Therapix Biosciences Ltd. Compositions and methods of potentiating antimicrobials
CA3067542A1 (en) * 2017-06-19 2018-12-27 Syddansk Universitet Bacitracin and/or daptomycin combined with cannabidiol for treatment of bacterial infections
WO2019198056A1 (en) * 2018-04-14 2019-10-17 Buzzelet Development And Technologies Ltd Terpene-enriched cannabinoid composition for treating conditions and/ or symptoms associated with a stressful event
WO2020000024A1 (en) * 2018-06-28 2020-01-02 Botanix Pharmaceuticals Ltd Antibacterial treatment using cannabinoid combinations
CA3111979A1 (en) * 2018-09-05 2020-03-12 Nemus Bioscience, Inc. Cannabinoids for the treatment of gram-positive infections including antibiotic-resistant bacterial strains
MX2021013656A (es) * 2019-05-06 2022-01-06 Univ British Columbia Formulaciones antibioticas de cannabinoides-terpenos.

Also Published As

Publication number Publication date
SG11202110779SA (en) 2021-10-28
JP2022532116A (ja) 2022-07-13
MX2021013656A (es) 2022-01-06
IL287729A (en) 2021-12-01
EP3965794A4 (en) 2023-01-18
CN113710263A (zh) 2021-11-26
US20230355573A1 (en) 2023-11-09
KR20220005066A (ko) 2022-01-12
US11744819B2 (en) 2023-09-05
AU2020270175A1 (en) 2021-12-02
WO2020223811A1 (en) 2020-11-12
US20220233494A1 (en) 2022-07-28
US20220218654A1 (en) 2022-07-14
EP3965794A1 (en) 2022-03-16

Similar Documents

Publication Publication Date Title
US20230355573A1 (en) Antibiotic cannabinoid-terpene formulations
CN103391774B (zh) 包含反式-肉桂醛的药物组合物及其在治疗感染中的用途
Fahle et al. Antibacterial effects of biologically active ingredients in hop provide promising options to fight infections by pathogens including multi-drug resistant bacteria
US20230248745A1 (en) Silver enhanced cannabinoid antibiotics
AU2009285564A1 (en) Methods of treatment using single doses of oritavancin
CN103384519B (zh) 抗微生物的组合物
CN114796188A (zh) 植物来源的黄酮抗菌化合物及其应用
US10758529B2 (en) Pharmaceutical compositions containing azaquinone for inhibiting clostridium difficile activity
Hamid et al. Effects of antimicrobial flavonoids against representative bacteria and fungi: a review of the literature
US20180021296A1 (en) Potentiated antimicrobial agents
HK40064842A (en) Antibiotic cannabinoid-terpene formulations
WO2025213249A1 (en) Silver enhanced cannabinoid antibiotics
KR102670265B1 (ko) 테트라메틸부틸하이드로퀴논을 유효성분으로 포함하는 황색포도상구균 바이오필름 형성 억제용 조성물
WO2015031579A2 (en) Methods for treating bacterial infections using oritavancin and polymyxins
AU2017235711B2 (en) Enhanced tulathromycin
CHOWDARY ROLE OF NARINGENIN ON THE ANTIBACTERIAL ACTIVITY OF SELECTED β-LACTAM ANTIBIOTICS
CN120860179A (zh) 赤松素联合多黏菌素在制备抗菌药物中的应用
AU2013202360B2 (en) Methods of treatment using single doses of oritavancin
CN113768919A (zh) 木犀草素在增效没食子酸烷基酯类化合物抗金黄色葡萄球菌作用中的新用途

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251021

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251222

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251229